Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment

Trial Profile

Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes: Study of Insulin Sensitivity in the 2 Types of Treatment

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2017

At a glance

  • Drugs Insulin detemir (Primary) ; Insulin glulisine (Primary)
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms TRICIDIA; TRICIDIA2
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 09 Sep 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov (NCT02048189)
    • 09 Sep 2015 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov (NCT02048189)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top